EyePoint Pharmaceuticals のニュースと活動

EyePoint Pharmaceuticalsはの一部です...

• Russell 3000;
• TOB Iconic 10,000.

％sは、株式相場表示 ％s（％s）の下にリストされている会社です。

20人の主要幹部と一緒に組織図を見る

EyePoint Pharmaceuticalsでもっとも検索された略歴

• Jay Duker, President, Chief Executive Officer and Director
• Wendy DiCicco, Director
• Nancy Lurker, Executive Vice Chairman of the Board

更新履歴 - ％sの

• Michael Campbellは、Chief Commercial Officerとして加わりました (2026年2月18日公開されたニュース).

アラートを作成
EyePoint Pharmaceuticals のエグゼクティブの異動をフォローします。

EyePoint PharmaceuticalsはThermo Fisher Scientific (アメリカ合衆国（米国）),Medtronic (アイルランド),Philips (オランダ王国)を含む1,235の競合企業を有します。

Popular M&A news in 医療機器

• Bridgepoint has announced the acquisition of Obagi Medical Products  (2026年6月4日に公開).
• ％sは、％s百万ドルの資金調達を発表しました。 (2026年6月2日に公開).
• Edap Tms将改名为FocalTherics。 (2026年6月1日に公開).

医療機器業界でのその他のコンタクトの提案

• Medtronic 社 Kweli Thompson - Executive Vice President and President, Neuroscience Portfolio
• Zimmer Biomet 社 Ivan Tornos - Chairman, President and Chief Executive Officer
• Illumina 社 Jacob Thaysen - Chief Executive Officer and Director

医療機器業界についてさらに知る

％sによる最新のプレスリリース

• EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint, Inc.
• EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint, Inc.
• EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - EyePoint, Inc.
• EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments - EyePoint, Inc.
• EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 - EyePoint, Inc.
• EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint, Inc.
• EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint, Inc.
• EyePoint Initiates Phase 3 Trials of Duravyu for DME
• EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments - EyePoint, Inc.
• EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema - EyePoint, Inc.
• View more press releases Close

％sについてのソーシャルメディア

• EyePoint Pharmaceuticals についてのウィキペディア,Google News & Yahoo Financeの記事
• EyePoint Pharmaceuticals についてのLinkedIn,ツイッター & YouTubeの記事